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Prognostic significance of p53 overexpression and mutation in colorectal
adenocarcinomas
DR Smith, C-Y Ji and H-S Goh
Colorectal Cancer Research Laboratory, Department of Colorectal Surgery, Singapore General Hospital, Singapore.
Summary The p53 tumour-suppressor gene is found altered in the majority of colorectal cancers. Lesions
include allelic loss, mutation of the gene and overexpression of the p53 protein. All of these lesions have been
analysed for prognostic significance, and whereas both mutation and allelic loss have been shown to be
reasonably useful markers of prognosis, the utility of overexpression of the p53 protein is more ambiguous.
Given that many authors use p53 overexpression as a marker for point mutation this issue is of some
importance. We have therefore examined 100 colorectal carcinomas for mutation of the p53 gene, as well as
overexpression of the p53 protein. Results show that whereas mutation of the p53 gene is associated with p53
overexpression, the degree of association depends, at least in part, upon the particular antibody used.
Moreover, although mutation of the p53 gene does provide prognostic information, overexpresssion of the p53
protein, as detected with two antibodies, does not. These results suggest that immunohistochemistry is not a
suitable alternative to direct detection of mutations in assessing prognosis in colorectal cancer patients.
Keywords: tumour suppressor; colon cancer
The p53 tumour-suppressor gene is the most commonly
altered gene in solid human neoplasia (Hollstein et al., 1991;
Levine et al., 1991). The p53 gene was first identified by its
ability to complex with SV40 large T antigen (Lane and
Crawford, 1979) and the adenovirus type 5 EIB 58KD
protein (Sarnow et al., 1982). Localisation of the gene
showed that the p53 gene resides at chromosomal location
Chl7pl3.1 (Isobe et al., 1986; McBride et al., 1986), a site
that is frequently found to have undergone allelic deletion in
many cancers (Baker et al., 1989; Takahashi et al., 1989;
Mulligan et al., 1990). The remaining allele of the p53 gene is
commonly found to be mutated (Baker et al., 1989, 1990;
Takahashi et al., 1989; Nigro et al., 1989). The wild-type
(non-mutated) protein has the ability to reduce or eliminate
the tumorigenic potential of a cell line (Chen et al., 1990).
The mutated protein has lost this ability, and shows
oncogenic activity (Hinds et al., 1989, 1990). Used alone in
transformation assays the mutated protein is able to
immortalise primary fibroblasts (Jenkins et al., 1984;
Rovinski and Benchimol, 1988), and when used in
conjunction with activated ras, mutated p53 can fully
transform primary fibroblasts (Parada et al., 1984; Eliyahu
et al., 1989; Hinds et al., 1990).
Wild-type p53 has a short half-life of about 15 min (Oren
et al., 1981), and is turned over rapidly by an ATP-dependent
degradation pathway (Gronostajski et al., 1984). Mutations
within the p53 gene often lead to proteins with a greater
stability, with half-lives of up to 20 h in some cases (Oren et
al., 1981; Reich et al., 1983). The mutant protein accumulates
within the malignant cell and can be readily detected by
immunohistochemistry, as opposed to normal cells, in which
the protein is essentially undetectable by normal methods
(Rodriguez et al., 1990). Mutations of the p53 gene often lead
to conformational changes within the p53 protein with the
resultant accessibility of epitopes normally unavailable for
antibody recognition (Cook and Milner, 1990).
Allelic loss of the p53 gene has been shown to occur in up
to 70% of colorectal cancers (Kern et al., 1989; Khine et al.,
1994), and is associated with tumour progression, particularly
the presence of distant organ metastasis (Khine et al., 1994).
In short-term studies, allele loss of p53 does not provide
prognostic information (O'Connell et al., 1992; Campo et al.,
1994; Khine et al., 1995), but in studies with longer follow-up
periods, allelic loss of one copy of the p53 gene is a
significant indicator of a poorer patient prognosis (Kern et
al., 1989; Laurent-Puig et al., 1992).
Point mutation of the p53 gene occurs in approximately
50% of colorectal carcinomas (Hollstein et al., 1991; Goh et
al., 1994), and is also associated with tumour progression
(Goh et al., 1994) and a poorer patient prognosis (Hamelin et
al., 1994; Goh et al., 1995), although this is not found by
some authors (Dix et al., 1994a, Table I).
Over-expression of the p53 protein has been reported to
occur in 24-72% of colorectal cancers, with a large part of
the variation residing in the specificities of the antibodies use
in these studies, and to a lesser extent to what the authors
define as overexpression (Rodriguez et al., 1990; Scott et al.,
1991; Starzynska et al., 1992; Remvikos et al., 1992;
Yamaguchi et al., 1992, 1993; Bell et al., 1993; Sun et al.,
1992; Bosari et al., 1994; Nathanson et al., 1994; Dix et al.,
1994b; Mulder et al., 1995). At least 11 studies (see Table II)
have examined p53 over-expression with respect to patient
survival in colorectal cancer patients (Scott et al., 1991;
Remvikos et al., 1992; Starzynska et al., 1992; Sun et al.,
1992; Yamaguchi et al., 1992, 1993; Bell et al., 1993; Bosari
et al., 1994; Dix et al., 1994a; Nathanson et al., 1994;
Mulder et al., 1995). Six of these studies found that
overexpression of the p53 gene is significantly associated
with a poorer patient prognosis in univariate analysis
(Remvikos et al., 1992; Starzynska et al., 1992; Yamaguchi
et al., 1992, 1993; Bosari et al., 1994; Dix et al., 1994a). The
remaining five studies do not detect a demonstrable
relationship between patient survival and nuclear p53
overexpression (Scott et al., 1991; Sun et al., 1992; Bell et
al., 1993; Nathanson et al., 1994; Mulder et al., 1995). Two
groups have noted a poorer patient prognosis associated
with the detection of immunoreactive p53 in the cytoplasm
of colorectal adenocarcinoma cells (Sun et al., 1992; Bosari
et al., 1994) although the significance of this remains
unclear. In this study we have examined p53 overexpression
and patient survival in a cohort in which information on
p53 mutation status is also examined.
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Materials and methods
Patients and tumours
Samples used in this study were from patients admitted to the
Department of Colorectal Surgery at Singapore General
Hospital. No initial chemotherapy, radiotherapy or hormonal
therapy was given before tumour excision. A portion
(approximately 1 g) of the surgically removed tumour was
snap frozen in liquid nitrogen at the time of surgery (within
20 min of resection) and stored at -80°C until required. The
remainder of the tumour sample was sent for histopatholo-
gical diagnosis and tumours were staged as Dukes' A-D
according to Turnbull's modification of Dukes' original
staging (Dukes, 1932; Turnbull et al., 1967). Control mucosa
(sited at least 10 cm proximal to the site of the tumour) was
also removed and similarly treated. Frozen tumour samples
were embedded into OCT freezing media (BDH, Poole, UK),
sections taken and stained with haematoxylin-eosin and
examined microscopically. Non-tumour regions were then
removed and samples processed as below. Patient follow-up
(mean 23.4 months, range 1-60 months) was established as
the time between surgery and last departmental contact
(scheduled follow-up, mail response or telephone contact) or
patient death. Death as a result of causes other than cancer
were treated as censored events.
Immunohistochemistry
Immunoreactive p53 was detected by the labelled streptavi-
din-biotin method (Warnke et al., 1980; Hsu et al., 1981).
Several contiguous 5 jim frozen sections were taken from
each case. One section was stained with haematoxylin-eosin
stain. Sections from immunohistochemistry were-allowed to
come to room temperature and they dehydrated in acetone
for 10 min. Following excessive rinsing in phosphate-buffered
saline (PBS) endogenous peroxidases were quenched by
incubation in 1.5 hydrogen peroxide, 50% ethanol and
0.5 x PBS for 15 min. Slides were then incubated with
blocking reagent for 30 min (Dako LSAB kit, Dako,
Carpinteria, CA, USA). Incubation with primary antibody
Table I Summary of studies examing the prognostic significance of
p53 point mutation in colorectal cancer
Cohort Per cent Univariate
Study size positive analysis
Hamelin et al. (1994) 85 52 P=0.003
Goh et al. (1995) 193 57 P=0.0054
Dix et al. (1994a)a 100 37 P=NS
This study 100 51 P=0.03
aDukes' stages B and C only
followed rinsing three times with PBS. Incubation at room
temperature with a 1:10 dilution of PAb 240 (Oncogene
Science, Uniondale, NY, USA) was carried out overnight,
and with a 1:40 dilution of PAb 1801 (Oncogene Science)
was for 30 min. Following three rinses with PBS slides were
incubated with linking antibody (Dako) for 10 min, followed
by 10 min with streptavidin-horseradish-peroxidase diluted
as recommended by the manufacturer and then incubated for
2 min with the chromagen 3,3'-diaminobenzidine tetrahy-
drochloride (DAB; Dako). After each incubation samples
were rinsed three times in PBS. Samples were then counter-
stained with haematoxylin for 1 min and nuclei blued under
running water. Slides were then dehydrated and mounted.
Mutation analysis
Analysis of colorectal carcinomas was undertaken exactly as
described in detail elsewhere (Smith et al., 1994a, b) and
cohort contains samples previously described (Smith et al.,
1994a, b; Goh et al., 1994, 1995). Briefly, a first-strand cDNA
copy was made from total RNA using random hexamers.
This was used as a template in a polymerase chain reaction to
amplify a 644 bp cDNA fragment of p53, which contains the
region known to contain 98% of all point mutations of the
p53 gene (Hollstein et al., 1991). This fragment was digested
with the restriction endonuclease MspI, fragments depho-
sphorylated with calf intestinal alkaline phosphatase and
labelled with 32P-y-ATP. The digestion products were then
analysed on a 6% polyacrylamide non-denaturing gel.
Samples were analysed by duplicate reverse transcriptase
polymerase chain reaction single-stranded conformation
polymorphism (RT-PCR-SSCP), and selected cases con-
firmed by DNA sequencing (Goh et al., 1995). After
autoradiography aberrant migration patterns, corresponding
to mutations of the p53 gene, can readily be detected.
Statistical analysis
Two by two tables were analysed by Fisher's exact test.
Kaplan-Meier survival plots were calculated using the SPSS
computer program (SPSS, Chicago, IL, USA) and analysed
by log-rank analysis.
Results
A total of 100 colorectal carcinomas were examined for the
presence of detectable levels of immunoreactive p53, as well
as for mutations of the p53 gene. All tumours were single
(non-synchronous, non-metachronous) adenocarcinomas. A
clinical summary of patients is shown in Table III.
Immunoreactive p53 was detected by the labelled streptavi-
din -biotin method. At no time was immunoreactive p53
Table II Summary of studies examing p53 protein overexpression and patient survival in colorectal cancer
Per cent Univariate
Study Tissue type Cohort size Antibody positive analysis
Bell et al. (1993) Fresh, frozen IodP PAB 421 45 P=NS
Bosari et al. (1994)a Parrafin block 206 PAb 1801 46 P=0.019
Dix et al. (1994a) Fresh, frozen 100 D07 46 P= 0.039
Mulder et al. (1995) Paraffin block 109 D07 72 P=NS
Nathanson et al. (1994) Paraffin block 84 PAb 1801 62 P=NS
Remvikos et al. (1992) Fresh, frozenb 78 PAb 240 67 P=0.03
Scott et al. (1991) Fresh, frozen 52 PAb 421 42 P=NS
Starzynska et al. (1992) Paraffin block 107 CM1 46 P=0.001
Sun et al. (1992)a Paraffin block 293 CM1 49 P=NS
Yamaguchi et al. (1992) Paraffin block 100 1801 61 P<0.05
Yamaguchi et al. (1993) Parrafin block 203 1801 59.6 P<0.05
This study Fresh, frozen 100 240 76 P=NS
1801 62 P=NS
aCytoplasmic staining associated with poorerpatient prognosis. bp53 content analysed by flowcytometry and
ELISA.p53 and prognosis in colorectal cancer
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detected in histologically normal control mucosa. Antibodies
PAb 1801 (Banks et al., 1989) and PAb 240 (Gannon et al.,
1990) were used to analyse each specimen, as evidence has
shown that not all antibodies have comparable reactivity
(Cook and Milner, 1990). Antibody PAb 1801 recognises an
epitope of the p53 protein between amino acids 72 and 79,
whereas PAb 240 recognises a denaturing-resistant epitope of
p53 between amino acids 156 and 335.
Immunoreactive p53 was detected in 62% of cases with
monoclonal antibody PAb 1801, and in 76% of cases with
monoclonal antibody PAb 240 (Figure 1). As has been
reported by other workers staining was predominantely
nuclear (Rodriguez et al., 1990; Scott et al., 1991; Remvikos
et al., 1992; Starzynska et al., 1992; Sun et al., 1992;
Yamaguchi et al., 1992; Bell et al., 1993; Bosari et al., 1994),
although some cases of cytoplasmic staining were noted. The
distribution of staining was variable with some tumours
showing extensive staining over almost the whole section
Table III Clinical summary of patients in relation to p53 overexpression and mutation
of the gene
PAb 240 PAb 1801 Mutation
Total Negative Positive Negative Positive Negative Positive
Number of patients 100 24 76 38 62 49 51
Sex
Male 53 10 43 18 35 26 27
Female 47 14 33 20 27 23 24
Age
Mean 64.0 66.5 63.2 64.8 63.4 63.8 64.1
Range 28-87 28-82 33-87 28-87 33-84 28-82 33-87
Location
Proximal 22 7 15 8 14 15 7
Distal 78 17 61 30 48 34 44
Tumour stage
Dukes' A 22 5 17 8 14 13 9
Dukes' B 23 6 17 13 9 12 10
Dukes' C 32 5 27 10 22 12 20
Dukes' D 24 8 16 7 17 12 12
Status
Alive 77 19 58 31 46 42 35
Dead 23 5 18 7 16 7 16
Figure 1 Overexpression ofp53 in colorectal adenocarcinoma. Figure shows immunostaining with monoclonal antibodies PAb 240
(a, c) and PAb 1801 (b). Also shown is a negative control (d, minus primary antibody). Immunoreactive p53 stains brown. Original
magnification x 100 (a, b) x 400 (c, d).p53 and prognosis in colorectal cancer
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while others showed discrete localised staining in only one or
two areas. Intensity of staining was also variable, with some
tumours showing intense staining, and other tumours
showing light staining. All tumours were qualitatively
assessed on staining intensity from 0 (no detectable
staining) to 4 (heavy staining over the majority of the
section). All assessments were undertaken by one author
(CYJ). Eighteen per cent ofthe tumours examined showed no
staining with either antibody, 6% showed reactivity with PAb
1801, but not with PAb 240; 20% showed evidence of
staining with antibody PAb 240, but not PAb 1801 and 56%
showed staining with both antibodies. The detection of
immunoreactive p53 by the two antibodies was significantly
associated (P<0.0001, Table IV).
Mutation of the p53 gene was detected by single-stranded
conformational polymorphisms (Orita et al., 1989a, b) using
the modification of Sakai and Tsuchida (1992) as described in
detail elsewhere (Smith et al., 1994a, b). Mutation of the p53
gene was detected in 51% of the tumours (Figure 2).
Point mutation ofthe p53 gene was weakly associated with
the presence of detectable levels of immunoreactive p53
(intensity scoring 1 to 4) as assessed by monoclonal antibody
PAb 1801 (P=0.02, Table IV). In contrast, mutation of the
p53 gene was strongly associated with the presence of
detectable levels of immunoreactive p53 (intensity scoring I
to 4) as assessed with monoclonal antibody PAb 240
(P<0.0001, Table IV). Indeed only 4% (2/51) of point
mutations of p53 were not associated with overexpression of
p53 protein as detected by monoclonal antibody PAb 240. In
contrast 27% (14/51) of mutations did not give rise to
detectable levels of p53 overexpression as assessed with
monoclonal antibody PAb 1801.
Patient survival was analysed in light of these lesions.
Kaplan-Meier plots were contructed with patients stratified
according to either PAb 1801 status (Figure 3), whereby all
tumours that showed any degree of staining were considered
positive for p53 overexpression or PAb 240 status (Figure 4),
whereby all tumours that showed any degree of staining were
considered positive for p53 overexpression and mutation
status (Figure 5). All plots were analysed by log-rank analysis
(Table V). The overexpression of p53 as detected by
monoclonal antibodies PAb 1801 or PAb 240 was not found
to be associated with a poorer patient prognosis (P=0.60 and
P=0.72 respectively, log-rank analysis). In contrast, and in
agreement with our earlier report (Goh et al., 1995) and with
others (Hamelin et ,al., 1994), mutation of p53 was
significantly associated with a poorer patient prognosis
(P=0.03, log-rank analysis). Further analysis of p53 over-
expression status with regards to the intensity of staining also
failed to detect any significant association with prognosis.
Discussion
In this report we have shown that mutation ofthe p53 gene is
associated with a poorer patient prognosis, whereas the
presence of detectable levels of immunoreactive p53 is not. In
this paper we have also shown that point mutation ofthe p53
gene is significantly associated with overexpression of the
Table IV Relationships between p53 overexpression as detected by
monoclonal antibodies PAb 1801, PAb 240 and point mutation of
the p53 gene
PAb 1801 PAb 240
Negative Positive Negative Positive
PM negative 24 25 22 27
PM positive 14 37 2 49
P, Fisher's exact P=0.02 P<0.0001
PAb 240 negative 18 6
PAb positive 20 56
P, Fisher's exact P<0.0001
'-603
'-310
'-271/281
'-234
'-194
-118
-72
1 2 3 4 5 6 7 8
Figure 2 Representative SSCP analysis of seven colorectal
adenocarcinomas. Representative SSCP of seven tumours (lanes
1-7). Position of the two complementary strands shown (joined
arrows). Lane 8 is a non-denatured control showing the position
of undenatured duplex. Aberrant migration bands are seen in
lanes 2, 3 and 4. Also indicated (single arrows) are duplex size
marker positions.
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Figure 3 Kaplan-Meier analysis of 100 colorectal cancer
patients stratified according to PAb 1801 overexpression status.
(- - -), No overexpression detected; ( ), overexpression
detected.
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1.0 represent as much as 20% of all mutations occurring
(Hamelin et al., 1994). In a study on 33 lung cancer cell
0.8 -l -------lines, Bodner et al. (1994) proposed that carcinomas with
mutations of the p53 gene could be divided into two classes,
0.6 those that led to high levels of protein overexpession and
were primarily mutations in exons 5-8, and those with
0.4 mutations that lead to low levels of overexpression, such as
0.2
nonsense mutations, splicing mutations and point mutations
outside exons 5-8. Although this is an attractive proposition,
0.0o it is not supported by Cripps et al. (1994), who found that
0 10 20 30 40 50 60 70 mutations in exon 6 are not associated with protein
Time of follow-up (months) stabilisation. Perhaps of greater concern is the accumulating
evidence that mutation per se is not enough to stabilise the
Ire 4 Kaplan-Meier analysis of 100 colorectal cancer protein and that additional factors may be required to
ents stratified according to PAb 240 overexpression status. stabilise a mutated protein for immunohistochemical detec-
-), No overexpression detected; (-), overexpression detected. tion (Wynford-Thomas, 1992).
In our cohort, protein overexpression was detected in the
absence of detectable mutation in 25% and 27% of cases
1.0 <, Lwith monoclonal antibodies PAb 1801 and PAb 240
respectively. Monoclonal antibody PAb 1801 recognises an
0.8 --------- - epitope between amino acids 72 and 79 and as such is able
0.6
to recognise p53 in both the 'wild-type' and 'mutant' forms
0.6 whereas PAb 240 recognises a denaturation-resistant epitope
0.4
on mutant p53 between amino acids 156 and 335, and is
specific for the 'mutant' form of the protein. As such, the
0.2 27% of tumours that showed overexpression of the p53 protein as detected by monoclonal antibody PAb 240 in the
0.0o absence of a mutation is somewhat surprising. Perhaps the
0 10 20 30 40 50 60 70 most obvious explanation would be that the SSCP was
Time of follow-up (months) failing to detect certain mutations. However dilution
experiments by other authors have shown SSCP to be very
re 5 Kaplan-Meier analysis of 100 colorectal cancer sensitive, with sensitivity ranging from 1.5-2% up to 6-
ents stratified according to p53 point mutation status. 12% dependent upon the exact nature of the mutation (Dix
-), No point mutation detected; (-), point mutation detected. et al., 1994b). Perhaps more convincing is the data of Cripps
et al. (1994), who show that certain point mutations are not
detected by SSCP, possibly because the mutation does not
V Log-rank analysis of Kaplan-Meier plots for patient sufficiently alter the conformation of the DNA strand in
'al in relationship to monoclonal antibody PAb 240 and PAb which it resides. However, these authors have further shown
1801 status and mutation status that a substantial proportion of tumours with stabilised p53
Patients dead P do not contain mutations in exons 5-8. It is possible then
Status Number (log-rank) that either mutations lying outside exon 5-8 are responsible
240 Negative 24 5 NS (0.72) for the overexpression of the protein, or alternate, non-
Positive 76 18 mutational pathways are responsible. Mutations outside the
coding region such as mutations in the promoter region
1801 Negative 38 7 NS (0.69) could lead to a dramatic up-regulation of the mRNA or
Positive 62 16 mutations in the 3'-untranslated region could directly affect
iutation Negative 49 7 0.03 RNA stability. Other mechanisms leading to a build-up of
Positive 51 16 p53 protein within the cell include damage to the ATP-
dependent degradation pathway of p53 (Gronostajski et al.,
1984; Wynford-Thomas, 1992), complexing with viral
proteins or amplification of the mdm2 gene (Vogelstein
and Kinzler, 1992).
in. However, increasingly it is being shown that the Perhaps the question that most urgently needs to be
lonship between mutation of the p53 gene and over- addressed is that ofthe biological function of the p53 protein
ssion of the protein is not a direct or absolute one. In within the neoplastic cell. Two questions in particular need to
study we found concordances of 61% and 71% for be addressed. Firstly, does the presence of a point mutation
)clonal antibodies PAb 1801 and PAb 240 respectively implicitly mean a non-functional protein and secondly, is the
le IV), figures in close agreement with those of Dix et al. presence of p53 protein overexpression in the absence of a
lb) on a similarly sized cohort of colorectal adenocarci- point mutation indicative of a functional or a non-functional
is who found a concordance of 69% with monoclonal protein. The partial answer to the first question is that
iody D07. In both studies some 10% of tumours extensive experimental work has indicated that the majority
)nstrated the presence of mutations that were not of point-mutated p53 molecules have lost the ability to
-iated with immunohistochemical overexpression of the suppress tumorigenesis (Levine et al., 1994). However
in (Dix et al., 1994b: 11%; this study PAb 1801: 14%, exceptions do exist, for example, mutation of codon Arg-
240: 2%); and some 20% of tumours that had evidence 175 to Cys-175 apparently results in a protein indistinguish-
verexpression of the protein, but failed to detect any able from wild-type (Ory et al., 1994), and moreover we have ~tion of the gene (Dix et at., 1994b: 20%; this study PAb recently shown that different point mutations of p53 are
25%; PAb 240: 27%). associated with markedly different biological impact on the
[though the majority of mutations of p53 in colorectal patient (Goh et al., 1995). These results suggest that all
-r are single-base missense mutations (Greenblatt et al., mutations of the p53 gene do not result in equally non-
), a proportion of tumours contain nonsense or frame functional proteins. The second question is more difficult.
mutations that will lead to truncated proteins and that Certain proposed mechanisms for build up ofp53 that do not
not express the epitope recognised by a particular involve point-mutation driven protein stabilisation may result
oody. Some authors propose that these mutations may in the accumulation of functional, wild-type p53, and as such
0
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may not be associated with a complete loss of function.
although it has been proposed that stabilisation of the
protein in some cases may result in functional inactivation
(Wynford-Thomas. 1992). The number and complex ways in
which p53 may be built up in a cell, and the uncertain effects
on suppressor activity means that it is unsurprising that p53
build-up is not directly associated with patient mortality.
Previous studies undertaken to assess the prognostic
significance of p53 overexpression in colorectal carcinomas
have yielded contradictory results (Scott et al.. 1991;
Remvikos et al.. 1992: Starzynska et al., 1992; Sun et al..
1992; Yamaguchi et al., 1992, 1993; Bell et al.. 1993; Bosari et
al., 1994; Dix et al., 1994a; Nathanson et al., 1994; Mulder et
al., 1995). Direct comparisons are difficult owing to the use of
many different monoclonal and polyclonal antibodies, the use
of fresh tissue samples and paraffin blocks, and a general lack
of consensus as to the number ofcells that need to be stained
for a tumour to be considered positive for p53 over-
expression. Although two studies (Sun et al.. 1992: Bosari
et al., 1994) have shown relatively convincing relationships
between the detection of cytoplasmic p53. this has not been
found by other authors (Mulder et al., 1995). It may be of
significance that both of these studies were relatively large
cohorts of paraffin-preserved samples. Until these factors are
effectively analysed, the importance of p53 protein over-
expression as a prognostic indicator will remain uncertain.
In contrast to Dix et al. (1994a), but in agreement with
our earlier report (Goh et al., 1995) and with others (Hamelin
et al., 1994), we find that mutation of the p53 gene is
associated with a poorer patient prognosis. A possible
explanation for the discrepancy between these studies may
lie in the composition of the patient cohorts. Whereas this
study (in line with the distribution of presenting cases in
Singapore) and the cohort of Hamelin et al. (1994) contain
approximately 20% of tumours examined originating on the
right of the colorectum (i.e. proximal to the splenic flexure).
the cohort of Dix et al. (1994a) contains 44% of tumours
originating proximal to the splenic flexure. This cohort is
typical of cohorts in developed nations that are undergoing a
marked proximal drift in the distribution of presenting cases
of colorectal adenocarinoma (Beart et al.. 1983). Interest-
ingly, we have recently completed an analysis of over 300
colorectal adenocarcinomas for mutation of the p53 gene and
find that whereas mutation of the p53 gene is strongly
associated with patient prognosis in carcinomas originating
distal to the splenic flexure, this relationship is not found in
carcinomas arising proximal to the splenic flexure (DR Smith.
J Elnatan. J Yao and H-S Goh, manuscript in preparation).
Hence equally mixed cohorts of proximal and distal colonic
adenocarcinomas may not show a relationship between
patient survival and mutation of the p53 gene.
The mechanism by which mutation of the p53 gene is
associated with a poorer patient prognosis is as yet unclear.
Mutated p53 proteins are oncogenic. capable of co-operating
with activated ras to fully transform primary rat fibroblasts
(Eliyahu et al., 1989: Parada et al.. 1984: Hinds et al., 1990).
Whether this effect only happens when the mutated p53 is
present in large excess of the endogeneous p53. or whether
mutant p53 is able to inactivate wild-type p53 by the so
called dominant negative mechanism whereby the mutant
protein introduces conformational changes in the wild-type
protein (Milner and Medcalf, 1991), remains unclear.
Furthermore, evidence that shows that mutated p53 may
envince 'gain of functions' not normally found in wild-type
p53 makes the situation particularly complex (Dittmer et al..
1993). It is clear however, both in this cohort and others
(Hamelin et al.. 1994: Goh et al.. 1995) that p53 point
mutation can provide prognostic information. and that p53
immunohistochemistry to detect immunoreactive p53.
although easily introduced into a clinical setting. is not an
acceptable surrogate for the more complex and technically
demanding direct detection of p53 gene mutations.
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